Why the study?
Does anticoagulation reduce stroke or systemic embolism in patients with subclinical atrial fibrillation?
Does anticoagulation reduce stroke or systemic embolism in patients with subclinical atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Routine anticoagulation for subclinical AF episodes under 24 hours is not clearly supported due to a small absolute reduction in stroke that is offset by an increased risk of major bleeding, highlighting the need for individualized patient management.
Subclinical" atrial fibrillation (AF) refers to short, asymptomatic episodes of atrial arrhythmia, typically lasting from a few minutes to several hours.[1] These episodes are often unnoticed by patients and are most commonly identified through continuous cardiac rhythm monitoring, particularly in individuals with implanted cardiac devices.Studies such as ASSERT II, REVEAL AF, PREDATE AF, and the DANISH LOOP trial have shown that approximately one-third of such patients exhibit subclinical AF. [2,3] How to cite this article: Vogiatzis I. Subclinical atrial fibrillation and anticoagulants.Where does the evidence lead us?
No takes yet. Share an insight, caveat, or question.
Ioannis Vogiatzis (2025) conducted an editorial in Subclinical atrial fibrillation (n=4,012). Apixaban vs. Aspirin (100 mg once daily) was evaluated on Incidence of stroke or systemic embolism (37% relative reduction, 95% CI 12-55%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: